ProtAffin AG starts Phase 1 study for lead product PA401 in inflammatory lung disease

28-Jun-2012 - Austria

ProtAffin AG announced that it has started dosing healthy volunteers in a Phase 1 clinical study in the UK with its novel investigational anti-inflammatory product, PA401.

PA401 is a modified form of the human chemokine IL-8. Human IL-8 (CXCL8) is a chemokine produced by macrophages and other cells and its primary function is the attraction of neutrophils to sites of acute and chronic inflammation. PA401 acts as a potent, targeted anti-inflammatory protein preventing the infiltration of neutrophils which is a hallmark of many respiratory diseases including chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances